Prevention of HIV/AIDS

Last updated

HIV prevention refers to practices that aim to prevent the spread of the human immunodeficiency virus (HIV). HIV prevention practices may be undertaken by individuals to protect their own health and the health of those in their community, or may be instituted by governments and community-based organizations as public health policies.

Contents

Prevention strategies

Interventions for the prevention of HIV include the use of:

AIDS Prevention - Condom dispensers in toilets AIDS Prevention - Condom dispensers in toilets (4612444296).jpg
AIDS Prevention - Condom dispensers in toilets

The consistent, correct use of condoms is one proven method for preventing the spread of HIV during sexual intercourse. [6] In high income countries, Prevention of Mother to Child Transmission Programs (PMTC) including HIV testing of pregnant women, antiretroviral treatment, [7] counselling about infant feeding, and safe obstetric practices (avoiding invasive procedures) have reduced mother-to-child transmission to less than 1%.

Treatment as prevention (TasP) is also effective; in sero-different couples (where one partner is HIV-positive and the other is HIV negative), HIV is significantly less likely to be transmitted to the uninfected partner if the HIV positive partner is on treatment. [8] It is now known that an if HIV-positive person has an undetectable viral load, there is no risk of HIV transmission to a sexual partner [9] [10] [11]

Increased risk of contracting HIV correlates with the presence of co-infections, particularly other sexually transmissible infections. Medical professionals recommend treatment or prevention of other infections such as herpes, hepatitis A, hepatitis B, hepatitis C, human papillomavirus, syphilis, gonorrhea, and tuberculosis as an indirect way to prevent the spread of HIV infection. Doctors treat these conditions with pharmaceutical interventions and/or vaccination. [12] Nevertheless, it is not known if treating other sexually transmitted infections on a population scale is effective in preventing HIV. [13]

Harm reduction and social strategies

Harm reduction is defined as "policies, programmes and practices that aim to minimise negative health, social and legal impacts associated with drug use, drug policies and drug laws". [14] The World Health Organization (WHO) recognizes that harm reduction is central to the prevention of HIV amongst people who inject drugs (PWID) and their sexual and drug using partners. [15] Social strategies do not require any drug or object to be effective, but rather require persons to change their behaviors to gain protection from HIV. Some social strategies include:[ citation needed ]

Each of these strategies has widely differing levels of efficacy, social acceptance, and acceptance in the medical and scientific communities.[ citation needed ]

Populations who access HIV testing are less likely to engage in behaviors with high risk of contracting HIV, [16] so HIV testing is almost always a part of any strategy to encourage people to change their behaviors to become less likely to contract HIV. Over 60 countries impose some form of travel restriction, either for short or long-term stays, for people infected with HIV. [17]

Advertising and campaigns

Persuasive messages delivered through health advertising and social marketing campaigns which are designed to educate people about the risks of HIV/AIDS and simple prevention strategies are also an important way of preventing HIV. These persuasive messages have successfully increased people's knowledge about HIV. More importantly, information sent out through advertising and social marketing also proves to be effective in promoting more favorable attitudes and intentions toward future condom use, though they did not bring significant change in actual behaviors except those were targeting at specific behavioral skills. [18] [19]

A 2020 systematic review of 16 studies found that financial education improved self-efficacy and lowered vulnerability to HIV in young people in low and middle income countries. Many of the studies in the review combined financial education with sexual health education and/or counselling. [20]

Research in health communication also found that importance of advocating critical skills and informing available resources are higher for people with lower social power, but not necessarily true for people with more power. African American audiences need to be educated about strategies they could take to efficiently manage themselves in health behaviors such as mood control, management of drugs, and proactive planning for sexual behaviors. However, these things are not as important for European Americans. [19]

Sexual contact

Condoms and gels

Condom in the shape of an AIDS ribbon Every6SecondsSomeoneContractsHIV.jpg
Condom in the shape of an AIDS ribbon
Various personal lubricants Gleitmittel Personal Lubricants.jpg
Various personal lubricants

Consistent condom use reduces the risk of heterosexual HIV transmission by about 80% over the long-term. [21] Where one partner of a couple has HIV infection, consistent condom use results in rates of HIV infection for the uninfected person below 1% per year. [22] Some data support the equivalence of internal condoms to latex condoms, but the evidence is not definitive. [23] As of January 2019, condoms are available inside 30% of prisons globally. [24] Use of the spermicide nonoxynol-9 may increase the risk of transmission because it causes vaginal and rectal irritation. [25] A vaginal gel containing tenofovir, a reverse transcriptase inhibitor, when used immediately before sex, was shown to reduce infection rates by roughly 40% among African women. [26]

Voluntary male circumcision

South Africa 1 millionth voluntary medical male circumcision South Africa 1 millionth Voluntary Medical Male Circumcision (40944402290).jpg
South Africa 1 millionth voluntary medical male circumcision

Studies conducted in sub-Saharan Africa have found that circumcision reduces the risk of HIV infection in heterosexual men between 38 and 66% over two years. [27] Based on these studies, the World Health Organization and UNAIDS both recommended male circumcision as a method of preventing female-to-male HIV transmission in 2007. [28] Whether it protects against male-to-female transmission is disputed [29] [30] and whether it is of benefit in developed countries and among men who have sex with men is undetermined. [31] [32] [33] For men who have sex with men there is some evidence that the penetrative partner has a lower chance of contracting HIV. [34] Some experts fear that a lower perception of vulnerability among circumcised men may result in more sexual risk-taking behavior, thus negating its preventive effects. [35] Women who have undergone female genital cutting have an increased risk of HIV. [36]

The African studies on which this information is based have been criticized for methodological flaws. [37] Svoboda and Howe compare them to the "lowest common denominator", citing "selection bias, randomization bias, experimenter bias, inadequate blinding, participant expectation bias, lack of placebo control, inadequate equipoise, excessive attrition of subjects, failure to investigate non-sexual HIV transmission, lead time bias, and time-out discrepancy." In addition, the 60% figure for risk reduction is dismissed as relative and misleading, with an absolute figure of only 1.3%, which is considered effectively meaningless given the "background noise produced by numerous sources of bias". They also point out that the United States has both the highest rates of circumcision and HIV/STD infections in the industrialized world, casting serious doubt that the former prevents the latter. There are also major epidemiological differences between regions: in Africa, HIV is commonly spread via inadequate infection prevention practices in health clinics, while in the US, the primary routes of infection are sharing equipment amongst people who use drugs and condomless anal intercourse among MSM. Additional criticisms are offered by George Hill: [38] "Our results clearly show that these African CRFs were methodologically flawed from start to finish... From the start, there was almost nothing correct with these studies. It was quite clear that these studies were unethical. They would never have been approved by a single ethics committee in the United States."

Education and health promotion

Programs encouraging sexual abstinence do not appear to affect subsequent HIV risk in high-income countries. [39] Evidence for a benefit from peer education is equally poor. [40] Comprehensive sexual education provided at school may decrease high risk behavior. [41] A substantial minority of young people continue to engage in high-risk practices despite HIV/AIDS knowledge, underestimating their own risk of becoming infected with HIV. [42]

Before exposure

Early treatment of HIV-infected people with antiretrovirals protected 96% of partners from infection. [43] [8] Pre-exposure prophylaxis with a daily dose of tenofovir with or without emtricitabine is effective in a number of groups, including men who have sex with men, couples where one is HIV positive, and young heterosexuals in Africa. [26] . Within the MSM community, the greatest barrier to PrEP use has been the stigma surrounding HIV and gay men. Gay men on PrEP have experienced "slut-shaming" [44] [45] . Numerous other barriers were identified, including lack of quality LGBTQ care, cost, and adherence to medication use. [46]

Universal precautions within the health-care environment are believed to be effective in decreasing the risk of HIV. [47] Intravenous drug use is an important risk factor and harm reduction strategies such as needle-exchange programmes and opioid substitution therapy appear effective in decreasing this risk. [48]

Needle exchange programs (also known as syringe exchange programs) are effective in preventing HIV among IDUs and in the broader community. [49] Pharmacy sales of syringes and physician prescription of syringes have been also found to reduce HIV risk. [50] Supervised injection facilities are also understood to address HIV risk in the most-at-risk populations. [51] Multiple legal and attitudinal barriers limit the scale and coverage of these "harm reduction" programs in the United States and elsewhere around the world. [51]

The American Centers for Disease Control and Prevention (CDC) conducted a study in partnership with the Thailand Ministry of Public Health to ascertain the effectiveness of providing people who inject drugs illicitly with daily doses of the antiretroviral drug tenofovir as a prevention measure. The results of the study revealed a 48.9% reduced incidence of the virus among the group of subjects who received the drug, in comparison to the control group who received a placebo. The principal investigator of the study stated in the Lancet medical journal: "We now know that pre-exposure prophylaxis can be a potentially vital option for HIV prevention in people at very high risk for infection, whether through sexual transmission or injecting drug use." [52]

After exposure

A course of antiretrovirals administered within 48 to 72 hours after exposure to HIV-positive blood or genital secretions is referred to as post-exposure prophylaxis. [53] The use of the single agent zidovudine reduces the risk of subsequent HIV infection fivefold following a needle stick injury. [53] Treatment is recommended after sexual assault when the perpetrators are known to be HIV positive, but is controversial when their HIV status is unknown. [54] Current treatment regimens typically use lopinavir/ritonavir and lamivudine/zidovudine or emtricitabine/tenofovir and may decrease the risk further. [53] The duration of treatment is usually four weeks [55] and is associated with significant rates of adverse effects (for zidovudine about 70% including: nausea 24%, fatigue 22%, emotional distress 13%, and headaches 9%). [56]

Follow-up care

Strategies to reduce recurrence rates of HIV have been successful in preventing reinfection. Treatment facilities encourage those previously treated for HIV return to ensure that the infection is being successfully managed. New strategies to encouraging retesting have been the use of text messaging and email. These methods of recall are now used along with phone calls and letters. [57]

Mother-to-child

Programs to prevent the transmission of HIV from mothers to children can reduce rates of transmission by 92–99%. [48] [58] This primarily involves the use of a combination of antivirals during pregnancy and after birth in the infant but also potentially include bottle feeding rather than breastfeeding. [58] [59] If replacement feeding is acceptable, feasible, affordable, sustainable and safe mothers should avoid breast-feeding their infants; however, exclusive breast-feeding is recommended during the first months of life if this is not the case. [60] If exclusive breast feeding is carried out the provision of extended antiretroviral prophylaxis to the infant decreases the risk of transmission. [61]

Vaccination

Various approaches for HIV vaccine development Various approaches for HIV vaccine development.jpg
Various approaches for HIV vaccine development

As of 2020, no effective vaccine for HIV or AIDS is known. [62] A single trial of the vaccine RV 144 found a partial efficacy rate around 30% and has stimulated optimism in the research community regarding developing a truly effective vaccine. [63] Further trials of the vaccine are ongoing. [64] [65]

Gene therapy

Certain mutations on the CCR5 gene have been known to make certain people unable to catch AIDS. Modifying the CCR5 gene using gene therapy can thus make people unable to catch it either. [66] [67]

Laws criminalizing HIV transmission have not been found an effective way to reduce HIV risk behavior, and may actually do more harm than good. In the past, many U.S. states criminalized the possession of needles without a prescription, even going so far as to arrest people as they leave private needle-exchange facilities. [68] In jurisdictions where syringe prescription status presented a legal barrier to access, physician prescription programs had shown promise in addressing risky injection behaviors. [69] Epidemiological research demonstrating that syringe access programs are both effective and cost-effective helped change state and local laws relating to needle-exchange program (NEP) operations and the status of syringe possession more broadly. [70] As of 2006, 48 states in the United States authorized needle exchange in some form or allowed the purchase of sterile syringes without a prescription at pharmacies. [71]

Removal of legal barriers to operation of NEPs and other syringe access initiatives has been identified as an important part of a comprehensive approach to reducing HIV transmission among injection drug users (IDUs). [70] Legal barriers include both "law on the books" and "law on the streets", i.e., the actual practices of law enforcement officers, [72] [73] which may or may not reflect the formal law. Changes in syringe and drug-control policy can be ineffective in reducing such barriers if police continue to treat syringe possession as a crime or participation in NEP as evidence of criminal activity. [74] Although most NEPs in the US are now operating legally, many report some form of police interference. [74]

Research elsewhere has shown similar misalignment between "law on the books" and "law on the streets". For example, in Kyrgyzstan, although sex work, syringe sales, and possession of syringes are not criminalized and possession of small drug amounts has been decriminalized, gaps remain between these policies and law enforcement knowledge and practice. [75] [76] [77] To optimize public health efforts targeting vulnerable groups, law enforcement personnel and public health policies should be closely aligned. Such alignment can be improved through policy, training, and coordination efforts. [77]

Quality in prevention

The EU-wide Joint Action on Improving Quality in HIV Prevention is seeking to increase the effectiveness of HIV prevention in Europe by using practical quality assurance (QA) and quality improvement (QI) tools. [78]

History

1980s

The Centers for Disease Control was the first organization to recognize the pandemic which came to be called AIDS. [79] Their announcement came on June 5, 1981, when one of their journals published an article reporting five cases of pneumonia, caused by Pneumocystis jirovecii , all in gay men living in Los Angeles. [80] [81]

In May 1983, scientists isolated a retrovirus which was later called HIV from an AIDS patient in France. [82] At this point, the disease called AIDS was proposed to be caused by HIV, and people began to consider prevention of HIV infection as a strategy for preventing AIDS.[ citation needed ]

In the 1980s, public policy makers and most of the public could not understand that the overlap of sexual and needle-sharing networks with the general community had somehow lead to many thousands of people worldwide becoming infected with HIV. [79] In many countries, leaders and most of the general public denied both that AIDS and the risk behaviors which spread HIV existed outside of concentrated populations. [79]

In 1987, the United States FDA approved AZT as the first pharmaceutical treatment for AIDS. [83] Around the same time, ACT UP was formed, with one of the group's first goals being to find a way to get access to pharmaceutical drugs to treat HIV. [84] When AZT was made publicly available, it was extremely expensive and unaffordable to all but the most wealthy AIDS patients. [85] The availability of medicine but the lack of access to it sparked large protests around FDA offices. [86] [87]

From 2003

In 2003, Swaziland and Botswana reported nearly four out of 10 people were HIV positive. [88] Festus Mogae, president of Botswana, admitted huge infrastructure problems to the international community and requested foreign intervention in the form of consulting in health care setup and antiretroviral drug distribution programs. [89] In Swaziland, the government chose not to immediately address the problem in the way that international health agencies advised, so many people died. [90] In world media, the governments of African countries began to similarly be described as participating in the effort to prevent HIV actively or less actively.

There came to be international discussion about why HIV rates in Africa were so high, because if the cause were known, then prevention strategies could be developed. Previously, some researchers had suggested that HIV in Africa was widespread because of unsafe medical practices which somehow transferred blood to patients through procedures such as vaccination, injection, or reuse of equipment. In March 2003, the WHO released a statement that almost all infections were, in fact, the result of unsafe practices in heterosexual intercourse. [91]

In response to the rising HIV rates, Cardinal Alfonso López Trujillo, speaking on behalf of the Vatican, said that not only was the use of condoms immoral, but also that condoms were ineffective in preventing HIV. [92] The cardinal was highly criticized by the world health community, who were trying to promote condom use as a way to prevent the spread of HIV. [93] [94] The WHO later conducted a study showing that condoms are 90% effective at preventing HIV. [92]

In 2001, the United States began a war in Afghanistan related to fighting the Taliban. The Taliban, however, had opposed local opium growers and the heroin trade; when the government of Afghanistan fell during the war, opium production was unchecked. By 2003, the world market had an increase in the available heroin supply; in former Soviet states especially, an increase in HIV infection was due to injection drug use. Efforts were renewed to prevent HIV related to sharing needles. [95] [96] [97] [98]

From 2011

In July 2011, it was announced by the WHO and UNAIDS that a once-daily antiretroviral tablet could significantly reduce the risk of HIV transmission in heterosexual couples. [99] These findings were based on the results of two trials conducted in Kenya and Uganda, and Botswana.

The Partners PrEP (pre-exposure prophylaxis) trial was funded by the Bill & Melinda Gates Foundation [100] and conducted by the International Clinical Research Center at the University of Washington. The trial followed 4758 heterosexual couples in Kenya and Uganda, in which one individual was HIV positive and the other was HIV negative. [99] The uninfected (HIV negative) partner was given either a once-daily tenofovir tablet, a once-daily combination tablet of tenofovir and emtricitabine, or a placebo tablet containing no antiretroviral drug. These couples also received counselling and had access to free male and female condoms. In couples taking tenofovir and tenofovir/emtricitabine, there was a 62% and 73% decrease, respectively, in the number of HIV infections as compared to couples who were receiving the placebo. [99]

A similar result was observed with the TDF2 trial, conducted by the United States Centers for Disease Control in partnership with the Botswana Ministry of Health. [101] The trial followed 1200 HIV negative men and women in Francistown, Botswana, a city known to have one of the world's highest HIV infection rates. [101] Participants received either a once-daily tenofovir/emtricitabine combination tablet or a placebo. In those taking the antiretroviral treatment, there was found to be a 63% decrease in the risk of acquiring HIV, as compared to those receiving the placebo. [99]

The HIV-1 virus has proved to be tenacious, inserting its genome permanently into patients' DNA, forcing patients to take a lifelong drug regimen to control the virus and prevent a fresh attack. Now, a team of Temple University School of Medicine researchers have designed a way to "snip out" the integrated HIV-1 genes for good. This is one important step on the path toward a permanent cure for AIDS. This is the first successful attempt to eliminate latent HIV-1 virus from human cells.

In a study published by the Proceedings of the National Academy of Sciences (PNAS), Khalili and colleagues detail how they created molecular tools to delete the HIV-1 proviral DNA.[ full citation needed ] When deployed, a combination of DNA-snipping enzyme called a nuclease and targeting strand of RNA called a guide RNA (gRNA) hunt down the viral genome and excise the HIV-1 DNA. From there, the cell's own gene repair machinery takes over, soldering the loose ends of the genome back together – resulting in virus-free cells.[ citation needed ]

Since HIV-1 is never cleared by the immune system, removal of the virus is required in order to cure the disease. The same technique could theoretically be used against a variety of viruses. The research shows that these molecular tools also hold promise as a therapeutic vaccine; cells armed with the nuclease-RNA combination proved impervious to HIV infection.

See also

Related Research Articles

<span class="mw-page-title-main">Safe sex</span> Ways to reduce the risk of acquiring STIs

Safe sex is sexual activity using methods or contraceptive devices to reduce the risk of transmitting or acquiring sexually transmitted infections (STIs), especially HIV. "Safe sex" is also sometimes referred to as safer sex or protected sex to indicate that some safe sex practices do not eliminate STI risks. It is also sometimes used colloquially to describe methods aimed at preventing pregnancy that may or may not also lower STI risks.

The management of HIV/AIDS normally includes the use of multiple antiretroviral drugs as a strategy to control HIV infection. There are several classes of antiretroviral agents that act on different stages of the HIV life-cycle. The use of multiple drugs that act on different viral targets is known as highly active antiretroviral therapy (HAART). HAART decreases the patient's total burden of HIV, maintains function of the immune system, and prevents opportunistic infections that often lead to death. HAART also prevents the transmission of HIV between serodiscordant same-sex and opposite-sex partners so long as the HIV-positive partner maintains an undetectable viral load.

Needle sharing is the practice of intravenous drug-users by which a needle or syringe is shared by multiple individuals to administer intravenous drugs such as heroin, steroids, and hormones. This is a primary vector for blood-borne diseases which can be transmitted through blood. People who inject drugs (PWID) are at an increased risk for Hepatitis C (HCV) and HIV due to needle sharing practices. From 1933 to 1943, malaria was spread between users in the New York City area by this method. Afterwards, the use of quinine as a cutting agent in drug mixes became more common. Harm reduction efforts including safe disposal of needles, supervised injection sites, and public education may help bring awareness on safer needle sharing practices.

<span class="mw-page-title-main">Microbicides for sexually transmitted infections</span> Pharmacologic agents and chemical substances

Microbicides for sexually transmitted infections are pharmacologic agents and chemical substances that are capable of killing or destroying certain microorganisms that commonly cause sexually transmitted infection.

Post-exposure prophylaxis, also known as post-exposure prevention (PEP), is any preventive medical treatment started after exposure to a pathogen in order to prevent the infection from occurring.

<span class="mw-page-title-main">Tenofovir disoproxil</span> Antiviral drug used to treat or prevent HIV and hepatitis infections

Tenofovir disoproxil, sold under the trade name Viread among others, is a medication used to treat chronic hepatitis B and to prevent and treat HIV/AIDS. It is generally recommended for use with other antiretrovirals. It may be used for prevention of HIV/AIDS among those at high risk before exposure, and after a needlestick injury or other potential exposure. It is sold both by itself and together in combinations such as emtricitabine/tenofovir, efavirenz/emtricitabine/tenofovir, and elvitegravir/cobicistat/emtricitabine/tenofovir. It does not cure HIV/AIDS or hepatitis B. It is available by mouth as a tablet or powder.

Male circumcision reduces the risk of human immunodeficiency virus (HIV) transmission from HIV positive women to men in high risk populations.

HIV/AIDS has been a public health concern for Latin America due to a remaining prevalence of the disease. In 2018 an estimated 2.2 million people had HIV in Latin America and the Caribbean, making the HIV prevalence rate approximately 0.4% in Latin America.

<span class="mw-page-title-main">Needlestick injury</span> Accidental puncture of skin causing contamination

A needlestick injury is the penetration of the skin by a hypodermic needle or other sharp object that has been in contact with blood, tissue or other body fluids before the exposure. Even though the acute physiological effects of a needlestick injury are generally negligible, these injuries can lead to transmission of blood-borne diseases, placing those exposed at increased risk of infection from disease-causing pathogens, such as the hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). Among healthcare workers and laboratory personnel worldwide, more than 25 blood-borne virus infections have been reported to have been caused by needlestick injuries. In addition to needlestick injuries, transmission of these viruses can also occur as a result of contamination of the mucous membranes, such as those of the eyes, with blood or body fluids, but needlestick injuries make up more than 80% of all percutaneous exposure incidents in the United States. Various other occupations are also at increased risk of needlestick injury, including law enforcement, laborers, tattoo artists, food preparers, and agricultural workers.

<span class="mw-page-title-main">Emtricitabine/tenofovir</span> Drug combination for HIV/AIDS prophylaxis and treatment

Emtricitabine/tenofovir, sold under the brand name Truvada among others, is a fixed-dose combination antiretroviral medication used to treat and prevent HIV/AIDS. It contains the antiretroviral medications emtricitabine and tenofovir disoproxil. For treatment, it must be used in combination with other antiretroviral medications. For prevention before exposure, in those who are at high risk, it is recommended along with safer sex practices. It does not cure HIV/AIDS. Emtricitabine/tenofovir is taken by mouth.

<span class="mw-page-title-main">HIV/AIDS</span> Spectrum of conditions caused by HIV infection

The human immunodeficiency virus (HIV) is a retrovirus that attacks the immune system. It can be managed with treatment. Without treatment it can lead to a spectrum of conditions including acquired immunodeficiency syndrome (AIDS).

<span class="mw-page-title-main">Pre-exposure prophylaxis for HIV prevention</span> HIV prevention strategy using preventative medication for HIV-negative individuals

Pre-exposure prophylaxis for HIV prevention, commonly known as PrEP, is a form of medication used to prevent HIV infection, the cause of HIV/AIDS.

<span class="mw-page-title-main">Sexually transmitted infection</span> Infection transmitted through human sexual behavior

A sexually transmitted infection (STI), also referred to as a sexually transmitted disease (STD) and the older term venereal disease (VD), is an infection that is spread by sexual activity, especially vaginal intercourse, anal sex, oral sex, or sometimes manual sex. STIs often do not initially cause symptoms, which results in a risk of passing the infection on to others. Symptoms and signs of STIs may include vaginal discharge, penile discharge, ulcers on or around the genitals, and pelvic pain. Some STIs can cause infertility.

Kenya has a severe, generalized HIV epidemic, but in recent years, the country has experienced a notable decline in HIV prevalence, attributed in part to significant behavioral change and increased access to ARV. Adult HIV prevalence is estimated to have fallen from 10 percent in the late 1990s to about 4.8 percent in 2017. Women face considerably higher risk of HIV infection than men but have longer life expectancies than men when on ART. The 7th edition of AIDS in Kenya reports an HIV prevalence rate of eight percent in adult women and four percent in adult men. Populations in Kenya that are especially at risk include injecting drug users and people in prostitution, whose prevalence rates are estimated at 53 percent and 27 percent, respectively. Men who have sex with men (MSM) are also at risk at a prevalence of 18.2%. Other groups also include discordant couples however successful ARV-treatment will prevent transmission. Other groups at risk are prison communities, uniformed forces, and truck drivers.

<span class="mw-page-title-main">HIV/AIDS in Mozambique</span>

Mozambique is a country particularly hard-hit by the HIV/AIDS epidemic. According to 2008 UNAIDS estimates, this southeast African nation has the 8th highest HIV rate in the world. With 1,600,000 Mozambicans living with HIV, 990,000 of which are women and children, Mozambique's government realizes that much work must be done to eradicate this infectious disease. To reduce HIV/AIDS within the country, Mozambique has partnered with numerous global organizations to provide its citizens with augmented access to antiretroviral therapy and prevention techniques, such as condom use. A surge toward the treatment and prevention of HIV/AIDS in women and children has additionally aided in Mozambique's aim to fulfill its Millennium Development Goals (MDGs). Nevertheless, HIV/AIDS has made a drastic impact on Mozambique; individual risk behaviors are still greatly influenced by social norms, and much still needs to be done to address the epidemic and provide care and treatment to those in need.

Since HIV/AIDS was first reported in Thailand in 1984, 1,115,415 adults had been infected as of 2008, with 585,830 having died since 1984. 532,522 Thais were living with HIV/AIDS in 2008. In 2009 the adult prevalence of HIV was 1.3%. As of 2016, Thailand had the highest prevalence of HIV in Southeast Asia at 1.1 percent, the 40th highest prevalence of 109 nations.

<span class="mw-page-title-main">HIV-affected community</span> Medical condition

The affected community is composed of people who are living with HIV and AIDS, plus individuals whose lives are directly influenced by HIV infection. This originally was defined as young to middle aged adults who associate with being gay or bisexual men, and or injection drug users. HIV-affected community is a community that is affected directly or indirectly affected by HIV. These communities are usually influenced by HIV and undertake risky behaviours that lead to a higher chance of HIV infection. To date HIV infection is still one of the leading cause of deaths around the world with an estimate of 36.8 million people diagnosed with HIV by the end of 2017, but there can particular communities that are more vulnerable to HIV infection, these communities include certain races, gender, minorities, and disadvantaged communities. One of the most common communities at risk is the gay community as it is commonly transmitted through unsafe sex. The main factor that contributes to HIV infection within the gay/bisexual community is that gay men do not use protection when performing anal sex or other sexual activities which can lead to a higher risk of HIV infections. Another community will be people diagnosed with mental health issues, such as depression is one of the most common related mental illnesses associated with HIV infection. HIV testing is an essential role in reducing HIV infection within communities as it can lead to prevention and treatment of HIV infections but also helps with early diagnosis of HIV. Educating young people in a community with the knowledge of HIV prevention will be able to help decrease the prevalence within the community. As education is an important source for development in many areas. Research has shown that people more at risk for HIV are part of disenfranchised and inner city populations as drug use and sexually transmitted diseases(STDs) are more prevalent. People with mental illnesses that inhibit making decisions or overlook sexual tendencies are especially at risk for contracting HIV.

A vaginal microbicide is a microbicide for vaginal use, generally as protection against the contraction of a sexually transmitted infection during vaginal sexual intercourse. Vaginal microbicides are topical gels or creams inserted into the vagina.

HIV in pregnancy is the presence of an HIV/AIDS infection in a woman while she is pregnant. There is a risk of HIV transmission from mother to child in three primary situations: pregnancy, childbirth, and while breastfeeding. This topic is important because the risk of viral transmission can be significantly reduced with appropriate medical intervention, and without treatment HIV/AIDS can cause significant illness and death in both the mother and child. This is exemplified by data from The Centers for Disease Control (CDC): In the United States and Puerto Rico between the years of 2014–2017, where prenatal care is generally accessible, there were 10,257 infants in the United States and Puerto Rico who were exposed to a maternal HIV infection in utero who did not become infected and 244 exposed infants who did become infected.

In January 2018, the provincial government of British Columbia (BC) began providing individuals at high risk of HIV infection with pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) at no cost. High risk individuals include men and trans women who have sex with men, people who inject drugs, and people who have sex with people living with HIV. One year following this policy change, which is delivered as part of the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE)'s Drug Treatment Program, almost 3,300 people have been prescribed with PrEP or PEP.

References

  1. ↑ "How to Use a Female Condom | CDC". www.cdc.gov. 2019-02-22. Retrieved 2019-10-31.
  2. ↑ "How to Use a Male Condom | CDC". www.cdc.gov. 2019-02-22. Retrieved 2019-10-31.
  3. ↑ "How to Use a Dental Dam | CDC". www.cdc.gov. 2019-02-22. Retrieved 2019-10-31.
  4. ↑ Nandra I (28 March 2008). "WHO and UNAIDS announce recommendations from expert consultation on male circumcision for HIV prevention". who.int. Archived from the original on April 11, 2007. Retrieved 3 July 2011.
  5. ↑ Siegfried N, Muller M, Deeks JJ, Volmink J (April 2009). Cochrane HIV/AIDS Group (ed.). "Male circumcision for prevention of heterosexual acquisition of HIV in men". The Cochrane Database of Systematic Reviews (2): CD003362. doi:10.1002/14651858.CD003362.pub2. PMID   19370585.
  6. ↑ Weller S, Davis K, et al. (Cochrane HIV/AIDS Group) (2002-01-21). "Condom effectiveness in reducing heterosexual HIV transmission". The Cochrane Database of Systematic Reviews. 2012 (1): CD003255. doi:10.1002/14651858.CD003255. PMC   8407100 . PMID   11869658.
  7. ↑ White AB, Mirjahangir JF, Horvath H, Anglemyer A, Read JS (October 2014). Cochrane HIV/AIDS Group (ed.). "Antiretroviral interventions for preventing breast milk transmission of HIV". The Cochrane Database of Systematic Reviews. 2014 (10): CD011323. doi:10.1002/14651858.CD011323. PMC   10576873 . PMID   25280769.
  8. 1 2 Anglemyer A, Rutherford GW, Horvath T, Baggaley RC, Egger M, Siegfried N, et al. (Cochrane HIV/AIDS Group) (April 2013). "Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples". The Cochrane Database of Systematic Reviews. 4 (4): CD009153. doi:10.1002/14651858.CD009153.pub3. PMC   4026368 . PMID   23633367.
  9. ↑ Castilla J, Del Romero J, Hernando V, Marincovich B, García S, Rodríguez C (September 2005). "Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV". Journal of Acquired Immune Deficiency Syndromes. 40 (1): 96–101. doi: 10.1097/01.qai.0000157389.78374.45 . PMID   16123689. S2CID   42271802.
  10. ↑ Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, et al. (July 2016). "Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy". JAMA. 316 (2): 171–81. doi: 10.1001/jama.2016.5148 . PMID   27404185.
  11. ↑ Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, et al. (June 2019). "Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study". Lancet. 393 (10189): 2428–2438. doi:10.1016/S0140-6736(19)30418-0. PMC   6584382 . PMID   31056293.
  12. ↑ "Home - Australian STI Management Guidelines". www.sti.guidelines.org.au. Retrieved 2020-07-25.
  13. ↑ Ng BE, Butler LM, Horvath T, Rutherford GW (March 2011). "Population-based biomedical sexually transmitted infection control interventions for reducing HIV infection". The Cochrane Database of Systematic Reviews (3): CD001220. doi:10.1002/14651858.CD001220.pub3. PMID   21412869.
  14. ↑ "What is harm reduction?". Harm Reduction International. Retrieved 2020-02-25.
  15. ↑ "Harm reduction". www.euro.who.int. 2020-02-25. Retrieved 2020-02-25.
  16. ↑ Weinhardt LS, Carey MP, Johnson BT, Bickham NL (September 1999). "Effects of HIV counseling and testing on sexual risk behavior: a meta-analytic review of published research, 1985-1997". American Journal of Public Health. 89 (9): 1397–405. doi:10.2105/ajph.89.9.1397. PMC   1508752 . PMID   10474559.
  17. ↑ "HIVTravel - Regulations on Entry, Stay, and Residence for PLHIV" . Retrieved 2012-02-26.
  18. ↑ Albarracín D, McNatt PS, Klein CT, Ho RM, Mitchell AL, Kumkale GT (March 2003). "Persuasive communications to change actions: an analysis of behavioral and cognitive impact in HIV prevention". Health Psychology. 22 (2): 166–77. doi:10.1037/0278-6133.22.2.166. PMC   4803280 . PMID   12683737.
  19. 1 2 Albarracín D, Gillette JC, Earl AN, Glasman LR, Durantini MR, Ho MH (November 2005). "A test of major assumptions about behavior change: a comprehensive look at the effects of passive and active HIV-prevention interventions since the beginning of the epidemic". Psychological Bulletin. 131 (6): 856–97. doi:10.1037/0033-2909.131.6.856. PMC   2713787 . PMID   16351327.
  20. ↑ Lee N, Beeler Stücklin S, Lopez Rodriguez P, El Alaoui Faris M, Mukaka I (2020). "Financial education for HIV-vulnerable youth, orphans, and vulnerable children: A systematic review of outcome evidence". Campbell Systematic Reviews. 16 (1): e1071. doi: 10.1002/cl2.1071 . ISSN   1891-1803. PMC   8356319 .
  21. ↑ Crosby R, Bounse S (March 2012). "Condom effectiveness: where are we now?". Sexual Health. 9 (1): 10–7. doi: 10.1071/SH11036 . PMID   22348628.
  22. ↑ "Condom Facts and Figures". WHO. August 2003. Archived from the original on October 18, 2012. Retrieved January 17, 2006.
  23. ↑ Gallo MF, Kilbourne-Brook M, Coffey PS (March 2012). "A review of the effectiveness and acceptability of the female condom for dual protection". Sexual Health. 9 (1): 18–26. doi:10.1071/SH11037. PMID   22348629.
  24. ↑ Moazen, B, Owusu, PN, Wiessner, P and Stöver, H. (2019), Coverage and Barriers Towards Condom Provision in Prisons: A Review of the EvidenceAvailability, Coverage and Barriers Towards Condom Provision in Prisons: A Review of the EvidenceInstitut für Suchtforschung (ISFF), Frankfurt, University of Applied Sciences.
  25. ↑ Baptista M, Ramalho-Santos J (November 2009). "Spermicides, microbicides and antiviral agents: recent advances in the development of novel multi-functional compounds". Mini Reviews in Medicinal Chemistry. 9 (13): 1556–67. doi:10.2174/138955709790361548. PMID   20205637.
  26. 1 2 Celum C, Baeten JM (February 2012). "Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence". Current Opinion in Infectious Diseases. 25 (1): 51–7. doi:10.1097/QCO.0b013e32834ef5ef. PMC   3266126 . PMID   22156901.
  27. ↑ Siegfried N, Muller M, Deeks JJ, Volmink J (April 2009). "Male circumcision for prevention of heterosexual acquisition of HIV in men". The Cochrane Database of Systematic Reviews (2): CD003362. doi:10.1002/14651858.CD003362.pub2. PMID   19370585.
  28. ↑ "WHO and UNAIDS announce recommendations from expert consultation on male circumcision for HIV prevention". World Health Organization. Mar 28, 2007. Archived from the original on April 11, 2007.
  29. ↑ Larke N (May 2010). "Male circumcision, HIV and sexually transmitted infections: a review". British Journal of Nursing. 19 (10): 629–34. doi:10.12968/bjon.2010.19.10.48201. PMC   3836228 . PMID   20622758.
  30. ↑ Eaton L, Kalichman SC (November 2009). "Behavioral aspects of male circumcision for the prevention of HIV infection". Current HIV/AIDS Reports. 6 (4): 187–93. doi:10.1007/s11904-009-0025-9. PMC   3557929 . PMID   19849961.
  31. ↑ Kim HH, Li PS, Goldstein M (November 2010). "Male circumcision: Africa and beyond?". Current Opinion in Urology. 20 (6): 515–9. doi:10.1097/MOU.0b013e32833f1b21. PMID   20844437. S2CID   2158164.
  32. ↑ Templeton DJ, Millett GA, Grulich AE (February 2010). "Male circumcision to reduce the risk of HIV and sexually transmitted infections among men who have sex with men". Current Opinion in Infectious Diseases. 23 (1): 45–52. doi:10.1097/QCO.0b013e328334e54d. PMID   19935420. S2CID   43878584.
  33. ↑ Wiysonge CS, Kongnyuy EJ, Shey M, Muula AS, Navti OB, Akl EA, Lo YR (June 2011). Wiysonge CS (ed.). "Male circumcision for prevention of homosexual acquisition of HIV in men". The Cochrane Database of Systematic Reviews (6): CD007496. doi:10.1002/14651858.CD007496.pub2. PMID   21678366.
  34. ↑ "It's time to talk top: The risk of insertive, unprotected anal sex - Australian Federation of AIDS Organisations". Archived from the original on 2014-06-25. Retrieved 2014-06-13.
  35. ↑ Eaton LA, Kalichman S (December 2007). "Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies". Current HIV/AIDS Reports. 4 (4): 165–72. doi:10.1007/s11904-007-0024-7. PMC   2937204 . PMID   18366947.
  36. ↑ Utz-Billing I, Kentenich H (December 2008). "Female genital mutilation: an injury, physical and mental harm". Journal of Psychosomatic Obstetrics and Gynaecology. 29 (4): 225–9. doi:10.1080/01674820802547087. PMID   19065392. S2CID   36904088.
  37. ↑ Svoboda, Steven; Van Howe, Robert (July 2013). "Out of Step: Fatal Flaws in the Latest AAP Policy Report on Neonatal Circumcision". Journal of Medical Ethics. 39 (7). BMJ: 434–441. doi:10.1136/medethics-2013-101346. JSTOR   43282781. PMID   23508208. S2CID   39693618.
  38. ↑ Boyle, G. J.; Hill, G. (2011). "Sub-Saharan African randomised clinical trials into male circumcision and HIV transmission: Methodological, ethical and legal concerns". Journal of Law and Medicine. 19 (2): 316–34. PMID   22320006.
  39. ↑ Underhill K, Operario D, Montgomery P (October 2007). "Abstinence-only programs for HIV infection prevention in high-income countries". The Cochrane Database of Systematic Reviews (4): CD005421. doi:10.1002/14651858.CD005421.pub2. PMID   17943855.
  40. ↑ Tolli MV (October 2012). "Effectiveness of peer education interventions for HIV prevention, adolescent pregnancy prevention and sexual health promotion for young people: a systematic review of European studies". Health Education Research. 27 (5): 904–13. doi: 10.1093/her/cys055 . PMID   22641791.
  41. ↑ Ljubojević S, Lipozenčić J (2010). "Sexually transmitted infections and adolescence". Acta Dermatovenerologica Croatica. 18 (4): 305–10. PMID   21251451.
  42. ↑ Patel VL, Yoskowitz NA, Kaufman DR, Shortliffe EH (September 2008). "Discerning patterns of human immunodeficiency virus risk in healthy young adults". The American Journal of Medicine. 121 (9): 758–64. doi:10.1016/j.amjmed.2008.04.022. PMC   2597652 . PMID   18724961.
  43. ↑ National Institute of Allergy and Infectious Diseases (NIAID), "Treating HIV-infected People with Antiretrovirals Protects Partners from Infection", NIH News, 2011 May
  44. ↑ Dubov A, Galbo P, Altice F, Fraenkel L (August 2018). "Stigma and Shame Experiences by MSM Who Take PrEP for HIV Prevention: A Qualitative Study". American Journal of Men's Health.
  45. ↑ "PrEP slutshaming is still alive and well – and it's harming us all" . Retrieved 2024-05-15.
  46. ↑
  47. ↑ Centers for Disease Control (CDC) (August 1987). "Recommendations for prevention of HIV transmission in health-care settings". MMWR Supplements. 36 (2): 1S–18S. PMID   3112554.
  48. 1 2 Kurth AE, Celum C, Baeten JM, Vermund SH, Wasserheit JN (March 2011). "Combination HIV prevention: significance, challenges, and opportunities". Current HIV/AIDS Reports. 8 (1): 62–72. doi:10.1007/s11904-010-0063-3. PMC   3036787 . PMID   20941553.
  49. ↑ World Health Organization. "Effectiveness of Sterile Needle and Syringe Programming in Reducing HIV/AIDS Among Injecting Drug Users" (PDF). Evidence for Action Technical Papers. Retrieved 7 January 2012.
  50. ↑ Macalino GE, Sachdev DD, Rich JD, Becker C, Tan LJ, Beletsky L, Burris S (June 2009). "A national physician survey on prescribing syringes as an HIV prevention measure". Substance Abuse Treatment, Prevention, and Policy. 4: 13. doi: 10.1186/1747-597X-4-13 . PMC   2700789 . PMID   19505336.
  51. 1 2 Beletsky L, Davis CS, Anderson E, Burris S (February 2008). "The law (and politics) of safe injection facilities in the United States". American Journal of Public Health. 98 (2): 231–7. doi:10.2105/ajph.2006.103747. PMC   2376869 . PMID   18172151. SSRN   1088019.
  52. ↑ Bourke E (14 June 2013). "Preventive drug could reduce HIV transmission among injecting drug users". The Conversation Australia. The Conversation Media Group. Retrieved 17 June 2013.
  53. 1 2 3 "HIV exposure through contact with body fluids". Prescrire International. 21 (126): 100–1, 103–5. April 2012. PMID   22515138.
  54. ↑ Linden JA (September 2011). "Clinical practice. Care of the adult patient after sexual assault". The New England Journal of Medicine. 365 (9): 834–41. doi: 10.1056/NEJMcp1102869 . PMID   21879901.
  55. ↑ Young TN, Arens FJ, Kennedy GE, Laurie JW, Rutherford GW (January 2007). "Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure". The Cochrane Database of Systematic Reviews. 2012 (1): CD002835. doi:10.1002/14651858.CD002835.pub3. PMC   8989146 . PMID   17253483.
  56. ↑ Kripke C (August 2007). "Antiretroviral prophylaxis for occupational exposure to HIV". American Family Physician. 76 (3): 375–6. PMID   17708137.
  57. ↑ Desai M, Woodhall SC, Nardone A, Burns F, Mercey D, Gilson R (August 2015). "Active recall to increase HIV and STI testing: a systematic review". Sexually Transmitted Infections. 91 (5): 314–23. doi: 10.1136/sextrans-2014-051930 . PMID   25759476.
  58. 1 2 Coutsoudis A, Kwaan L, Thomson M (October 2010). "Prevention of vertical transmission of HIV-1 in resource-limited settings". Expert Review of Anti-Infective Therapy. 8 (10): 1163–75. doi:10.1586/eri.10.94. PMID   20954881. S2CID   46624541.
  59. ↑ Siegfried N, van der Merwe L, Brocklehurst P, Sint TT (July 2011). "Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection". The Cochrane Database of Systematic Reviews (7): CD003510. doi:10.1002/14651858.CD003510.pub3. PMID   21735394.
  60. ↑ "WHO HIV and Infant Feeding Technical Consultation Held on behalf of the Inter-agency Task Team (IATT) on Prevention of HIV – Infections in Pregnant Women, Mothers and their Infants – Consensus statement" (PDF). October 25–27, 2006. Archived (PDF) from the original on April 9, 2008. Retrieved March 12, 2008.
  61. ↑ Horvath T, Madi BC, Iuppa IM, Kennedy GE, Rutherford G, Read JS (January 2009). "Interventions for preventing late postnatal mother-to-child transmission of HIV". The Cochrane Database of Systematic Reviews. 2009 (1): CD006734. doi:10.1002/14651858.CD006734.pub2. PMC   7389566 . PMID   19160297.
  62. ↑ UNAIDS (May 18, 2012). "The quest for an HIV vaccine".
  63. ↑ Reynell L, Trkola A (2012-03-02). "HIV vaccines: an attainable goal?". Swiss Medical Weekly. 142: w13535. doi: 10.4414/smw.2012.13535 . PMID   22389197.
  64. ↑ U.S. Army Office of the Surgeon General (March 21, 2011). "HIV Vaccine Trial in Thai Adults". ClinicalTrials.gov. Retrieved June 28, 2011.
  65. ↑ U.S. Army Office of the Surgeon General (June 2, 2010). "Follow up of Thai Adult Volunteers With Breakthrough HIV Infection After Participation in a Preventive HIV Vaccine Trial". ClinicalTrials.gov.
  66. ↑ Cornu TI, Mussolino C, Bloom K, Cathomen T (2015). "Editing CCR5: a novel approach to HIV gene therapy". Gene Therapy for HIV and Chronic Infections. Advances in Experimental Medicine and Biology. Vol. 848. pp. 117–30. doi:10.1007/978-1-4939-2432-5_6. ISBN   978-1-4939-2431-8. PMID   25757618.
  67. ↑ "Gene Therapy for Controlling HIV Shows Early Promise". WebMD.
  68. ↑ Case P, Meehan T, Jones TS (1998). "Arrests and incarceration of injection drug users for syringe possession in Massachusetts: implications for HIV prevention". Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 18 (Suppl 1): S71-5. doi: 10.1097/00042560-199802001-00013 . PMID   9663627.
  69. ↑ Macalino GE, Sachdev DD, Rich JD, Becker C, Tan LJ, Beletsky L, Burris S (June 2009). "A national physician survey on prescribing syringes as an HIV prevention measure". Substance Abuse Treatment, Prevention, and Policy. 4 (1): 13. doi: 10.1186/1747-597X-4-13 . PMC   2700789 . PMID   19505336.
  70. 1 2 Burris S, Finucane D, Gallagher H, Grace J (August 1996). "The legal strategies used in operating syringe exchange programs in the United States". American Journal of Public Health. 86 (8): 1161–6. doi:10.2105/ajph.86.8_pt_1.1161. PMC   1380633 . PMID   8712281.
  71. ↑ Chris Barrish (10 June 2006). "To stop AIDS 'breeding ground' needle exchange a must, many say". The News Journal . pp. A1, A5. Archived from the original on 2 September 2006. Retrieved 10 June 2006.
  72. ↑ Burris S, Blankenship KM, Donoghoe M, Sherman S, Vernick JS, Case P, et al. (2004). "Addressing the "risk environment" for injection drug users: the mysterious case of the missing cop". The Milbank Quarterly. 82 (1): 125–56. doi:10.1111/j.0887-378x.2004.00304.x. PMC   2690204 . PMID   15016246. SSRN   937013.
  73. ↑ Beletsky L, Burris S, Macalino GE (2005). "Attitudes of Police Officers Towards Syringe Access, Occupational Needle-Sticks, and Drug Use: A Qualitative Study of One City Police Department in the United States". Int'l. J. Drug Pol'y. 16 (4): 267–274. doi:10.1016/j.drugpo.2005.01.009. S2CID   57946984. SSRN   872756.
  74. 1 2 Beletsky L, Grau LE, White E, Bowman S, Heimer R (February 2011). "The roles of law, client race and program visibility in shaping police interference with the operation of US syringe exchange programs". Addiction. 106 (2): 357–65. doi:10.1111/j.1360-0443.2010.03149.x. PMC   3088513 . PMID   21054615.
  75. ↑ CIS News (2009). "Kyrgyzstan takes an official course towards humanization of its policy towards drug users".{{cite journal}}: Cite journal requires |journal= (help)
  76. ↑ Eurasian Harm Reduction Network (2011). "Implementation of the political declaration and plan of action on international cooperation towards an integrated and balanced strategy to counter the world drug problem". Eurasian Harm Reduction Network.
  77. 1 2 Beletsky L, Thomas R, Smelyanskaya M, Artamonova I, Shumskaya N, Dooronbekova A, et al. (December 2012). "Policy reform to shift the health and human rights environment for vulnerable groups: the case of Kyrgyzstan's Instruction 417". Health and Human Rights. 14 (2): 34–48. PMID   23568946.
  78. ↑ "Quality Action". www.qualityaction.eu.
  79. 1 2 3 Merson MH, O'Malley J, Serwadda D, Apisuk C (August 2008). "The history and challenge of HIV prevention". Lancet. 372 (9637): 475–88. doi:10.1016/S0140-6736(08)60884-3. PMID   18687461. S2CID   26554589.
  80. ↑ Anonymous (1981). "Pneumocystis pneumonia—Los Angeles". Morbidity and Mortality Weekly Report (30): 250–52.
  81. ↑ Sepkowitz KA (June 2001). "AIDS--the first 20 years". The New England Journal of Medicine. 344 (23): 1764–72. doi: 10.1056/NEJM200106073442306 . PMID   11396444.
  82. ↑ Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. (May 1983). "Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)". Science. 220 (4599): 868–71. Bibcode:1983Sci...220..868B. doi:10.1126/science.6189183. JSTOR   1690359. PMID   6189183. S2CID   390173.
  83. ↑ Brown J (20 March 1987). "AEGiS-FDA: Approval of AZT". aegis.com. AIDS Education Global Information System. Archived from the original on 29 June 2011. Retrieved 2 July 2011.
  84. ↑ "ACT UP 1987 Wall Street Action - List of Demands". actupny.org. March 1987. Retrieved 2 July 2011.
  85. ↑ "ACT UP/ NY Chronology 1989". actupny.org. 2003. Retrieved 2 July 2011.
  86. ↑ "Police Arrest AIDS Protesters Blocking Access to FDA Offices". Los Angeles Times. 11 Oct 1988.
  87. ↑ Loth R (12 October 1988). "AIDS Protests close FDA Headquarters". Boston Globe.
  88. ↑ Carroll, Rory (2 January 2003). "Swaziland has world's highest Aids rate". The Guardian . London: GMG. ISSN   0261-3077. OCLC   60623878 . Retrieved 2 July 2011.
  89. ↑ Boseley S (11 July 2003). "Bush vows to join Africa's war on Aids". The Guardian . London: GMG. ISSN   0261-3077. OCLC   60623878 . Retrieved 2 July 2011.
  90. ↑ "Bogus Aids cures flood Swaziland". mg.co.za. Mail & Guardian. 30 December 2003. Retrieved 2 July 2011.
  91. ↑ de Santis D (14 March 2003). "Expert group stresses that unsafe sex is primary mode of transmission of HIV in Africa". who.int. World Health Organization. Archived from the original on August 27, 2004. Retrieved 2 July 2011.
  92. 1 2 Bradshaw, Steve (9 October 2003). "Vatican: condoms don't stop Aids". the Guardian. Retrieved 21 July 2021. The Aids virus is roughly 450 times smaller than the spermatozoon. The spermatozoon can easily pass through the 'net' that is formed by the condom.
  93. ↑ Stanford P (22 April 2008). "Obituary: Cardinal Alfonso López Trujillo". The Guardian . London: GMG. ISSN   0261-3077. OCLC   60623878 . Retrieved 2 July 2011.
  94. ↑ Devichand, Mukul (27 June 2004). "EU criticises Vatican's condom 'bigotry'". BBC News. Retrieved 21 July 2021.
  95. ↑ Parfitt T (October 2003). "Drug addiction and HIV infection on rise in Tajikistan". Lancet. 362 (9391): 1206. doi:10.1016/S0140-6736(03)14560-6. PMID   14570036. S2CID   11892428.
  96. ↑ Griffin N, Khoshnood K (July 2010). "Opium trade, insurgency, and HIV/AIDS in Afghanistan: relationships and regional consequences". Asia-Pacific Journal of Public Health. 22 (3 Suppl): 159S–167S. doi:10.1177/1010539510374524. PMID   20566549. S2CID   206615556.
  97. ↑ Hankins CA, Friedman SR, Zafar T, Strathdee SA (November 2002). "Transmission and prevention of HIV and sexually transmitted infections in war settings: implications for current and future armed conflicts". AIDS. 16 (17): 2245–52. doi: 10.1097/00002030-200211220-00003 . PMID   12441795. S2CID   5739709.
  98. ↑ Todd CS, Abed AM, Strathdee SA, Scott PT, Botros BA, Safi N, Earhart KC (September 2007). "HIV, hepatitis C, and hepatitis B infections and associated risk behavior in injection drug users, Kabul, Afghanistan". Emerging Infectious Diseases. 13 (9): 1327–31. doi:10.3201/eid1309.070036. PMC   2857281 . PMID   18252103.
  99. 1 2 3 4 "UNAIDS and WHO hail new results showing that a once-daily pill for HIV-negative people can prevent them from acquiring HIV". unaids.org. 13 July 2011. Retrieved 4 March 2012.
  100. ↑ "HIV & AIDS Information :: The efficacy of PrEP - The Partners PrEP trial". aidsmap.com. Archived from the original on 16 May 2012. Retrieved 4 March 2012.
  101. 1 2 "HIV & AIDS Information :: The efficacy of PrEP - The TDF2 trial". aidsmap.com. 2012. Archived from the original on 24 May 2019. Retrieved 4 March 2012.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.